MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Regeneron Pharmaceuticals Inc

Ouvert

SecteurSoins de santé

592.9 -0.28

Résumé

Variation du prix de l'action

24h

Actuel

Min

583.66

Max

599.49

Chiffres clés

By Trading Economics

Revenu

-423M

918M

Ventes

69M

3.8B

P/E

Moyenne du Secteur

14.641

57.333

BPA

12.07

Rendement du dividende

0.63

Marge bénéficiaire

24.219

Employés

15,106

EBITDA

-534M

1.1B

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+47.02% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.63%

2.63%

Prochains Résultats

29 avr. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-13B

62B

Ouverture précédente

593.18

Clôture précédente

592.9

Score Technique

By Trading Central

Confiance

Very Strong Bullish Evidence

Regeneron Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 févr. 2025, 12:13 UTC

Résultats

Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD

22 avr. 2025, 10:51 UTC

Actualités

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

28 févr. 2025, 12:00 UTC

Actualités

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4 févr. 2025, 11:58 UTC

Résultats

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

4 févr. 2025, 11:37 UTC

Résultats

Regeneron Pharma Sees 2025 Adjusted R&D $5B-$5.2B >REGN

4 févr. 2025, 11:37 UTC

Résultats

Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN

4 févr. 2025, 11:36 UTC

Résultats

Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN

4 févr. 2025, 11:35 UTC

Résultats

Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN

4 févr. 2025, 11:35 UTC

Résultats

Regeneron Pharma 4Q Adj EPS $12.07 >REGN

4 févr. 2025, 11:34 UTC

Résultats

Regeneron Pharma 4Q U.S. Net Sales for Eylea HD, Eylea Rose 2% to $1.5B >REGN

4 févr. 2025, 11:34 UTC

Résultats

Regeneron Pharma: 4Q Dupixent Global Net Sales Recorded by Sanofi Rose 15% to $3.7B >REGN

4 févr. 2025, 11:32 UTC

Résultats

Regeneron Pharma Board OKs Additional $3 Billion Share Repurchase >REGN

4 févr. 2025, 11:31 UTC

Résultats

Regeneron Pharma Initiates Quarterly Cash Dividend Program >REGN

31 janv. 2025, 08:30 UTC

Acquisitions, Fusions, Rachats

It's Bananas, but Stock Splits Can Pay Off. Here Are 5 Likely Contenders. -- Barrons.com

28 janv. 2025, 10:30 UTC

Actualités

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

31 oct. 2024, 13:58 UTC

Résultats

Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom -- IBD

31 oct. 2024, 10:52 UTC

Résultats

Regeneron Earnings Top Views For Biotech Giant -- IBD

31 oct. 2024, 10:34 UTC

Résultats

Regeneron Pharma 3Q Adj EPS $12.46 >REGN

31 oct. 2024, 10:33 UTC

Résultats

Regeneron Pharma 3Q EPS Cut 43c by Acquired IPR&D Charge >REGN

31 oct. 2024, 10:33 UTC

Résultats

Regeneron Pharma 3Q U.S. Sales for Eylea HD, Eylea Rose 3% to $1.54B >REGN

31 oct. 2024, 10:32 UTC

Résultats

Regeneron Pharma: 3Q Dupixent Global Net Sales Recorded by Sanofi Rose 23% to $3.82B >REGN

31 oct. 2024, 10:30 UTC

Résultats

Regeneron Pharma 3Q Rev $3.72B >REGN

31 oct. 2024, 10:30 UTC

Résultats

Regeneron Pharma 3Q EPS $11.54 >REGN

31 oct. 2024, 10:30 UTC

Résultats

Regeneron Pharma 3Q Net $1.34B >REGN

25 oct. 2024, 20:25 UTC

Résultats

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

1 août 2024, 11:50 UTC

Résultats

Regeneron Stock Climbs After Strong Second-Quarter Performance -- IBD

1 août 2024, 10:37 UTC

Résultats

Regeneron Pharma 2Q Adj EPS $11.56 >REGN

1 août 2024, 10:30 UTC

Résultats

Regeneron Pharma 2Q EPS $12.41 >REGN

1 août 2024, 10:30 UTC

Résultats

Regeneron Pharma 2Q Net $1.43B >REGN

1 août 2024, 10:30 UTC

Résultats

Regeneron Pharma 2Q Rev $3.55B >REGN

Comparaison

Variation de prix

Regeneron Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

47.02% hausse

Prévisions sur 12 Mois

Moyen 881.75 USD  47.02%

Haut 1,120 USD

Bas 547 USD

Basé sur 21 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

21 ratings

17

Achat

3

Maintien

1

Vente

Score Technique

By Trading Central

554.18 / 603.77Support & Résistance

Court Terme

Very Strong Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.